Olodaterol (BI1744) High

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 3

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

CompletedNCT01040728

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2010-01-31Updated: 2014-06-30

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

CompletedNCT01040689

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2010-01-31Updated: 2014-06-30

Related Papers

The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies.

2014-08-0934 citations